Micro-X Reports $3.1M Cash, $3.2M Operating Outflow, and Multiple Milestones

Progress on Clinical and Security Imaging Fronts

Micro-X Ltd (ASX:MX1) has marked significant strides in its CT imaging programs this quarter, notably commencing a human imaging pilot study for its Head CT scanner at the Royal Melbourne Hospital. This pilot phase aims to refine imaging algorithms using initial human head scans, setting the stage for a larger trial involving over 100 patients comparing Micro-X’s device against conventional hospital CT systems. The company also completed its second Head CT test bench ahead of deployment at the Royal Adelaide Hospital, unlocking a $0.4 million milestone under the Australian Medical Research Future Fund program.

Meanwhile, the Full Body CT project advanced through a critical design review, a key technical milestone that paved the way for manufacturing a full-sized engineering prototype. This achievement triggered a $1.6 million milestone payment from the US government’s ARPA-H program, supporting Micro-X’s efforts to demonstrate core imaging capabilities on physical test objects.

US Department of Homeland Security Contract Extension

On the security front, Micro-X secured a $1.3 million contract extension from the US Department of Homeland Security to accelerate software and machine learning development for its Checkpoint threat detection system. The company has completed manufacturing of the second and third Checkpoint units, which will join the first prototype for ongoing government evaluation. Despite previous US government shutdowns, Micro-X reports no material impact on development timelines.

Commercial Engagements and Market Outreach

Commercially, Micro-X hosted senior representatives from the Malaysian Ministry of Health, following their distributor IMS’s successful tender to supply Rover Plus units to the Malaysian government. The company also showcased its Rover Plus mobile digital radiology system at major healthcare conferences in Miami and Philadelphia, targeting Latin American and sports medicine markets. Rover sales continue to build, with the first hospital sale under a US supply agreement completed and further discussions underway.

Financial Position and Funding Outlook

Financially, Micro-X reported a cash balance of $3.1 million as at 30 June 2026, with net operating cash outflows of $3.2 million for the quarter. Operational cash inflows included $2 million from Australian government milestone payments and $1 million from US security contracts, offset by $7.8 million in operating expenses. The company also secured $3 million in borrowings during the quarter, partially mitigating cash burn. Product sales receipts were modest at $0.2 million, though post-quarter sales of $0.6 million were confirmed.

Looking ahead, Micro-X expects to receive $8.1 million in contracted development program receipts from FY27 onwards, contingent on milestone achievements. The company is close to finalising a convertible note placement targeting institutional and sophisticated investors to strengthen its funding base. Management anticipates improved cash flows in coming quarters, aided by an anticipated $2 million R&D tax incentive rebate expected in October 2026.

Upcoming Investor Engagements

Micro-X has scheduled an Investor Open Day at its Tonsley Innovation Precinct headquarters in early September, offering stakeholders a chance to review ongoing commercial and development activities firsthand. Additionally, a quarterly investor call is planned for 4 August 2026 to discuss results and outlook.